HUYABIO International Overview
- Year Founded
-
2004

- Status
-
Private
- Employees
-
105

- Latest Deal Type
-
Debt - PPP
HUYABIO International General Information
Description
Operator of a biotechnology company intended to accelerate the global development of novel biopharmaceutical product opportunities. The company bridges the gap between the international development process and the global biopharma market while reducing risk, enabling medical professionals to accelerate product development and maximize value globally.
Contact Information
Website
www.huyabio.comCorporate Office
- 12531 High Bluff Drive
- Suite 138
- San Diego, CA 92130
- United States
Corporate Office
- 12531 High Bluff Drive
- Suite 138
- San Diego, CA 92130
- United States
HUYABIO International Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Debt - PPP | 03-May-2020 | Completed | Clinical Trials - General | |||
3. Later Stage VC | 22-Apr-2015 | Completed | Clinical Trials - General | |||
2. Later Stage VC | 27-Mar-2012 | $7.61M | $12.6M | Completed | Pre-Clinical Trials | |
1. Seed Round | 07-Apr-2009 | $5M | $5M | Completed | Pre-Clinical Trials |
HUYABIO International Comparisons
Industry
Financing
Details
HUYABIO International Competitors (11)
One of HUYABIO International’s 11 competitors is Alkermes, a Formerly VC-backed company based in Dublin, Ireland.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Alkermes | Formerly VC-backed | Dublin, Ireland | ||||
Tris Pharma | Private Debt Financed | Monmouth Junction, NJ | ||||
CMP Pharma | Private Equity-Backed | Farmville, NC | ||||
Durect | Formerly VC-backed | Cupertino, CA | ||||
Par Pharmaceutical Companies | Formerly PE-Backed | Woodcliff Lake, NJ |
HUYABIO International Patents
HUYABIO International Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220370456-A1 | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors | Pending | 05-May-2021 | ||
US-20220370458-A1 | Shp2 inhibitor monotherapy and uses thereof | Pending | 05-May-2021 | ||
US-20210386708-A1 | Sulcardine administration for treatment of acute atrial fibrillation | Active | 12-Jun-2020 | ||
US-11813245-B2 | Sulcardine administration for treatment of acute atrial fibrillation | Active | 12-Jun-2020 | ||
US-20240058304-A1 | Sulcardine administration for treatment of acute atrial fibrillation 94919.0739.717301us | Pending | 12-Jun-2020 | A61K31/4025 |
HUYABIO International Signals
HUYABIO International FAQs
-
When was HUYABIO International founded?
HUYABIO International was founded in 2004.
-
Where is HUYABIO International headquartered?
HUYABIO International is headquartered in San Diego, CA.
-
What is the size of HUYABIO International?
HUYABIO International has 105 total employees.
-
What industry is HUYABIO International in?
HUYABIO International’s primary industry is Drug Discovery.
-
Is HUYABIO International a private or public company?
HUYABIO International is a Private company.
-
What is HUYABIO International’s current revenue?
The current revenue for HUYABIO International is
. -
How much funding has HUYABIO International raised over time?
HUYABIO International has raised $60.6M.
-
Who are HUYABIO International’s competitors?
Alkermes, Tris Pharma, CMP Pharma, Durect, and Par Pharmaceutical Companies are some of the 11 competitors of HUYABIO International.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »